Hester Bios

Market Cap: Small Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE782E01017
NSEID: HESTERBIO
BSEID: 524669

INR

1,653.40

9 (0.55%)

BSENSE

Dec 05

BSE+NSE Vol: 3.75 k

{
  "main_header": {
    "sid": 324228,
    "name": "Hester Bios",
    "stock_name": "Hester Bios",
    "full_name": "Hester Biosciences Ltd",
    "name_url": "stocks-analysis/hester-bios",
    "exchange": 1,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,653.40",
    "chg": 9,
    "chgp": "0.55%",
    "dir": 1,
    "prev_price": "1,644.40",
    "mcapval": "1,406.53 Cr",
    "mcap": "Small Cap",
    "scripcode": 524669,
    "symbol": "HESTERBIO",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE782E01017",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "3.75 k",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/hester-bios-324228-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Hester Bios Sees Revision in Market Evaluation Amidst Mixed Financial Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/hester-bios-downgraded-to-strong-sell-amid-weak-fundamentals-and-bearish-technicals-3737110",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/HesterBios_mojoScore_3737110.png",
        "date": "2025-11-30 10:24:43",
        "description": "Hester Bios, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting a more cautious outlook. This shift follows a detailed reassessment of the company’s financial health, valuation, and technical indicators, highlighting challenges amid some positive financial trends."
      },
      {
        "title": "Is Hester Bios technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-hester-bios-technically-bullish-or-bearish-3727438",
        "imagepath": "",
        "date": "2025-11-25 08:27:35",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Overview of Current Technical Landscape</strong></p>\n<p>The technical trend for Hester Bios has recently transitioned to a bearish stance as of 24 November 2025, signalling increased downside pressure. This shift is corroborated by multiple technical indicators across various timeframes, suggesting a cautious outlook for traders and investors alike.</p>\n<p>Key momentum indicators such as the Moving Average Convergence Divergence (MACD) are bearish on both weekly and monthly charts, indicating sustained negative momentum. Similarly, the Know Sure Thing (KST) oscillator aligns with this bearish sentiment across weekly and monthly periods, reinforcing the downward trend.</p>\n<p>Moving averages on the daily chart also confirm a bearish bias, with the current price trading below key averages, whi..."
      },
      {
        "title": "Hester Biosciences Faces Technical Momentum Shift Amid Market Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/hester-biosciences-faces-intensified-downtrend-amid-technical-momentum-shift-3727346",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/HesterBioscienc_technicaldot_3727346.png",
        "date": "2025-11-25 08:03:55",
        "description": "Hester Biosciences, a key player in the Pharmaceuticals & Biotechnology sector, is currently exhibiting a notable shift in its technical momentum. Recent market data reveals a transition in the company’s technical indicators, reflecting evolving investor sentiment and price dynamics amid broader market pressures."
      },
      {
        "title": "Hester Biosciences Forms Death Cross Signalling Potential Bearish Trend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/hester-biosciences-forms-death-cross-signalling-bearish-trend-ahead-3726139",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/HesterBioscienc_dealthcross_3726139.png",
        "date": "2025-11-24 18:00:36",
        "description": "Hester Biosciences has recently formed a Death Cross, a technical pattern where the 50-day moving average crosses below the 200-day moving average, often interpreted as a signal of weakening momentum and potential bearish trend ahead for the stock."
      },
      {
        "title": "Are Hester Bios latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-hester-bios-latest-results-good-or-bad-3698322",
        "imagepath": "",
        "date": "2025-11-13 19:31:43",
        "description": "Hester Biosciences' latest financial results for the quarter ended September 2025 present a complex picture of profitability and operational challenges. The company reported a consolidated net profit of ₹14.45 crores, reflecting a notable year-on-year growth of 76.22%. However, this profit surge is largely attributed to extraordinary other income, which constituted a significant portion of the profit before tax, raising concerns about the sustainability of earnings from core operations.\n\nIn contrast, net sales for the same quarter declined by 15.20% year-on-year, indicating a significant drop in revenue generation. This decline is compounded by a sequential decrease of 15.62% from the previous quarter, suggesting ongoing challenges in the company's core animal healthcare business. The operating profit, excluding other income, fell to ₹11.71 crores, marking a decline of 38.88% compared to the previous year, ..."
      },
      {
        "title": "Hester Biosciences Faces Mixed Financial Trends Amidst Strong Cash Flow and Sales Decline",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/hester-biosciences-financial-trend-declines-from-very-positive-to-positive-amid-rising-costs-and-falling-sales-3697344",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/HesterBioscienc_fintrenddot_3697344.png",
        "date": "2025-11-13 11:01:13",
        "description": "Hester Biosciences reported strong operating cash flow and a solid return on capital for the quarter ending September 2025, despite a decline in net sales and profit before tax. The company's low debt-equity ratio indicates a robust balance sheet, but mixed market performance raises concerns about future growth sustainability."
      },
      {
        "title": "Hester Biosciences Q2 FY26: Profit Surge Masks Underlying Revenue Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/hester-biosciences-q2-fy26-profit-surge-masks-underlying-revenue-concerns-3697691",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/HesterBioscienc_quaterlyResult_3697691.png",
        "date": "2025-11-13 09:22:30",
        "description": "Hester Biosciences Ltd., a pioneering animal healthcare company, reported consolidated net profit of ₹14.45 crores for Q2 FY26, marking a remarkable 76.22% year-on-year surge from ₹8.20 crores in Q2 FY25. However, the impressive bottom-line growth conceals a troubling narrative: net sales declined 15.20% year-on-year to ₹70.97 crores, whilst sequential revenue dropped 15.62% from Q1 FY26's ₹84.11 crores. The stock, trading at ₹1,712.35 with a market capitalisation of ₹1,456.67 crores, has declined 30.86% over the past year, significantly underperforming the Sensex's 9.11% gain by nearly 40 percentage points."
      },
      {
        "title": "How has been the historical performance of Hester Bios?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-hester-bios-3695235",
        "imagepath": "",
        "date": "2025-11-13 00:12:47",
        "description": "Answer:\nThe historical performance of Hester Bios shows a steady growth in net sales and profitability over the years, with some fluctuations in specific metrics.\n\nBreakdown:\nHester Bios has demonstrated a consistent increase in net sales from INR 178.07 crore in March 2019 to INR 311.10 crore in March 2025. Total operating income has followed a similar trend, reaching INR 311.10 crore in March 2025, up from INR 266.09 crore in March 2023. The company's total expenditure, excluding depreciation, was INR 250.05 crore in March 2025, slightly down from INR 250.90 crore in March 2024. Operating profit (PBDIT) has shown resilience, with a figure of INR 64.97 crore in March 2025, compared to INR 64.29 crore in March 2024. Profit before tax was INR 35.47 crore in March 2025, an increase from INR 27.34 crore in March 2024, while profit after tax rose to INR 24.73 crore from INR 16.56 crore in the previous year. The..."
      },
      {
        "title": "Why is Hester Bios falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-hester-bios-fallingrising-3693425",
        "imagepath": "",
        "date": "2025-11-12 22:07:46",
        "description": "As of 12-Nov, Hester Biosciences Ltd is experiencing a price increase, currently at Rs 1,698.00, reflecting a rise of 57.2 points or 3.49%. The stock has shown a strong performance today, outperforming its sector by 2.51% and achieving a consecutive gain over the last four days, with a total increase of 6.65% during this period. It reached an intraday high of Rs 1,748, although it also faced volatility, trading within a wide range of Rs 169.1. Despite this positive movement, the stock has a mixed performance in the longer term, with a year-to-date decline of 29.03% and a one-year return of -34.09%. The company has reported positive financial results, including a 63.93% growth in net profit and strong operating cash flow, but it also faces concerns regarding its long-term fundamental strength, with a low return on capital employed and high debt levels.\n\nIn the broader market context, Hester Biosciences has o..."
      }
    ],
    "total": 5418,
    "sid": "324228",
    "stock_news_url": "https://www.marketsmojo.com/news/hester-biosciences-324228"
  },
  "announcements": [
    {
      "details": "Hester Biosciences Limited has informed the Exchange regarding Board meeting held on November 06, 2019.",
      "source": "NSE",
      "caption": "Hester Biosciences Limited - Outcome of Board Meeting",
      "datetime": "06-Nov-2019"
    },
    {
      "details": "Hester Biosciences Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates",
      "source": "NSE",
      "caption": "Hester Biosciences Limited - Analysts/Institutional Investor Meet/Con. Call Updates",
      "datetime": "31-Oct-2019"
    },
    {
      "details": " <table><tr><td>There is Discrepancies in earlier filed Voting Results. So we have rectified the error and uploaded revised file. </td></tr></table>",
      "source": "NSE",
      "caption": "Shareholders meeting",
      "datetime": "05-Aug-2019"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Hester Biosciences Ltd has declared <strong>70%</strong> dividend, ex-date: 06 Aug 25",
          "dt": "2025-08-06",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Hester Biosciences Ltd has announced <strong>1:2</strong> bonus issue, ex-date: 27 Sep 12",
          "dt": "2012-09-27",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "",
      "data": [
        {
          "txt": "Hester Biosciences Ltd has announced <strong>2:5</strong> rights issue, ex-date: 29 May 06",
          "dt": "2006-05-29",
          "middle_text": "Rights Issue"
        }
      ]
    }
  ]
}

News and Views

Hester Bios Sees Revision in Market Evaluation Amidst Mixed Financial Signals

2025-11-30 10:24:43

Hester Bios, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting a more cautious outlook. This shift follows a detailed reassessment of the company’s financial health, valuation, and technical indicators, highlighting challenges amid some positive financial trends.

Is Hester Bios technically bullish or bearish?

2025-11-25 08:27:35

Overview of Current Technical Landscape

The technical trend for Hester Bios has recently transitioned to a bearish stance as of 24 November 2025, signalling increased downside pressure. This shift is corroborated by multiple technical indicators across various timeframes, suggesting a cautious outlook for traders and investors alike.

Key momentum indicators such as the Moving Average Convergence Divergence (MACD) are bearish on both weekly and monthly charts, indicating sustained negative momentum. Similarly, the Know Sure Thing (KST) oscillator aligns with this bearish sentiment across weekly and monthly periods, reinforcing the downward trend.

Moving averages on the daily chart also confirm a bearish bias, with the current price trading below key averages, whi...

Hester Biosciences Faces Technical Momentum Shift Amid Market Challenges

2025-11-25 08:03:55

Hester Biosciences, a key player in the Pharmaceuticals & Biotechnology sector, is currently exhibiting a notable shift in its technical momentum. Recent market data reveals a transition in the company’s technical indicators, reflecting evolving investor sentiment and price dynamics amid broader market pressures.

Hester Biosciences Forms Death Cross Signalling Potential Bearish Trend

2025-11-24 18:00:36

Hester Biosciences has recently formed a Death Cross, a technical pattern where the 50-day moving average crosses below the 200-day moving average, often interpreted as a signal of weakening momentum and potential bearish trend ahead for the stock.

Are Hester Bios latest results good or bad?

2025-11-13 19:31:43

Hester Biosciences' latest financial results for the quarter ended September 2025 present a complex picture of profitability and operational challenges. The company reported a consolidated net profit of ₹14.45 crores, reflecting a notable year-on-year growth of 76.22%. However, this profit surge is largely attributed to extraordinary other income, which constituted a significant portion of the profit before tax, raising concerns about the sustainability of earnings from core operations. In contrast, net sales for the same quarter declined by 15.20% year-on-year, indicating a significant drop in revenue generation. This decline is compounded by a sequential decrease of 15.62% from the previous quarter, suggesting ongoing challenges in the company's core animal healthcare business. The operating profit, excluding other income, fell to ₹11.71 crores, marking a decline of 38.88% compared to the previous year, ...

Hester Biosciences Faces Mixed Financial Trends Amidst Strong Cash Flow and Sales Decline

2025-11-13 11:01:13

Hester Biosciences reported strong operating cash flow and a solid return on capital for the quarter ending September 2025, despite a decline in net sales and profit before tax. The company's low debt-equity ratio indicates a robust balance sheet, but mixed market performance raises concerns about future growth sustainability.

Hester Biosciences Q2 FY26: Profit Surge Masks Underlying Revenue Concerns

2025-11-13 09:22:30

Hester Biosciences Ltd., a pioneering animal healthcare company, reported consolidated net profit of ₹14.45 crores for Q2 FY26, marking a remarkable 76.22% year-on-year surge from ₹8.20 crores in Q2 FY25. However, the impressive bottom-line growth conceals a troubling narrative: net sales declined 15.20% year-on-year to ₹70.97 crores, whilst sequential revenue dropped 15.62% from Q1 FY26's ₹84.11 crores. The stock, trading at ₹1,712.35 with a market capitalisation of ₹1,456.67 crores, has declined 30.86% over the past year, significantly underperforming the Sensex's 9.11% gain by nearly 40 percentage points.

How has been the historical performance of Hester Bios?

2025-11-13 00:12:47

Answer: The historical performance of Hester Bios shows a steady growth in net sales and profitability over the years, with some fluctuations in specific metrics. Breakdown: Hester Bios has demonstrated a consistent increase in net sales from INR 178.07 crore in March 2019 to INR 311.10 crore in March 2025. Total operating income has followed a similar trend, reaching INR 311.10 crore in March 2025, up from INR 266.09 crore in March 2023. The company's total expenditure, excluding depreciation, was INR 250.05 crore in March 2025, slightly down from INR 250.90 crore in March 2024. Operating profit (PBDIT) has shown resilience, with a figure of INR 64.97 crore in March 2025, compared to INR 64.29 crore in March 2024. Profit before tax was INR 35.47 crore in March 2025, an increase from INR 27.34 crore in March 2024, while profit after tax rose to INR 24.73 crore from INR 16.56 crore in the previous year. The...

Why is Hester Bios falling/rising?

2025-11-12 22:07:46

As of 12-Nov, Hester Biosciences Ltd is experiencing a price increase, currently at Rs 1,698.00, reflecting a rise of 57.2 points or 3.49%. The stock has shown a strong performance today, outperforming its sector by 2.51% and achieving a consecutive gain over the last four days, with a total increase of 6.65% during this period. It reached an intraday high of Rs 1,748, although it also faced volatility, trading within a wide range of Rs 169.1. Despite this positive movement, the stock has a mixed performance in the longer term, with a year-to-date decline of 29.03% and a one-year return of -34.09%. The company has reported positive financial results, including a 63.93% growth in net profit and strong operating cash flow, but it also faces concerns regarding its long-term fundamental strength, with a low return on capital employed and high debt levels. In the broader market context, Hester Biosciences has o...

View All News